Read & Download your Issue of Thursday – March 04 FNN News

A retrospective analysis of clinical efficacy of ribavirin in adults hospitalized with severe COVID-19

• Coronavirus disease-2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) swept rapidly throughout the world.
• So far, no therapeutics have yet proven to be effective.
• Ribavirin was recommended for the treatment of COVID-19 in China because of its in vitro activity.
• However, evidence supporting its clinical use with good efficacy is still lacking.
• In hospitalized adult patients with severe COVID-19, no significant benefit was observed with ribavirin treatment.

Source: ScienceDirect

Maternal Vaccines – Safety in pregnancy

• Vaccination during pregnancy is important for active immunity of the mother against serious infectious diseases, and also for passive immunity of the neonate to infectious diseases with high morbidity and mortality.
• Live viral vaccines are contraindicated during pregnancy.
• Vaccines safe to be administered to all pregnant ladies are tetanus diphtheria, acellular pertussis and the inactivated influenza vaccine.
• Other vaccines to be offered to women at risk are hepatitis A & B, pneumococcal, meningococcal, yellow fever, typhoid and cholera.

Source: ScienceDirect

Hydroxychloroquine with azithromycin in patients hospitalized for mild and moderate COVID-19

• This study aims to assess the efficacy of hydroxychloroquine in combination with azithromycin in terms of clinical and biochemical outcomes in adult patients with COVID-19 hospitalized for acute respiratory distress syndrome (ARDS), and to describe the occurrence of adverse events.
• Patients treated with hydroxychloroquine combined with azithromycin and the control group had similar clinical outcomes.
• This therapeutic regimen was considered ineffective in hospitalized patients with mild to moderate COVID-19 related ARDS and was associated with few non-severe adverse events.

Source: ScienceDirect

Recent updates in COVID-19 with emphasis on inhalation therapeutics: nanostructured and targeting systems

• The current world health threat posed by the novel coronavirus disease of 2019 (COVID-19) calls for the urgent development of effective therapeutic options.
• In this review, they underline the genomic structure of COVID-19, recent modes of virus transmission with measures to control the infection, pathogenesis, clinical presentation of SARS-CoV-2, and how much the virus affects the lung.
• This review also focuses on the safe and efficient delivery of usable targeted therapies using designed nanocarriers.

Source: ScienceDirect

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

• The ChAdOx1 nCoV-19 (AZD1222) vaccine has been approved for emergency use by the UK regulatory authority.
• The planned roll-out in the UK will involve vaccinating people in high-risk categories with their first dose immediately, and delivering the second dose 12 weeks later.
• Here, they provide both a further prespecified pooled analysis of trials of ChAdOx1 nCoV-19 and exploratory analyses of the impact on immunogenicity and efficacy of extending the interval between priming and booster doses

Source: The Lancet

Synthesis of silver nanoparticles using gum Arabic: Evaluation of its inhibitory action on Streptococcus mutans causing dental caries and endocarditis

• Streptococcus mutans are an oral pathogen that causes dental caries, endocarditis, and systemic dysfunctions, an alternative antibacterial solution from silver nanoparticles (AgNPs) are investigated.
• The smaller the size, the greater the antibacterial and antiviral potential the particles exhibit.
• The biophysical characteristics of AgNPs the presence of phenols, alcohols, amides, sulfoxide, flavanoids, terpenoids and steroids.
• The potent antibiotic action over S. mutans seen with the synthesized NPs, paves the way for the development of novel dental care products.
• Also, the small-sized NPs promote its applicability in COVID-19 pandemic containment.

Source: ScienceDirect

• Read more from FADIC Blog, with many articles with evidence based articles.
• Learn More Through FADIC® – Online Programs & Mini-Courses.
• Listen Now to FADIC Podcast focusing on varieties of pharmacist perspectives in specialties.
• Read More Now about FADIC Pharmacy Events to get more Experience.

Course Copyrights:

All Courses is meant for SINGLE user use only.
If more than one person acceced this course, they will be BLOCKED Forever.

Why FADIC 2021 Pharmacotherapy Daily News (FNN) ?

• It helps to keep up with the literature!
• Provide you with the Updated with the latest in your clinical practice. Wherever you are, and Whenever you need!
• Help you to share in the advance in clinical career. In addition to adding an impressive image to the pharmacists all-around!

Subscribe to FADIC 2021 Pharmacotherapy Daily News (FNN), for a publication of E-News

Read & Download FNN Issue 8 of April 2020 FNN News